Amgen today announced that it has completed its acquisition of Horizon plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
“Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses,” said Bob Bradway, Amgen’s chairman and CEO. “We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases.”
The compelling strategic and financial rationale for the acquisition includes:
- Alignment with Amgen’s core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases.
- Strengthening of Amgen’s leading inflammation portfolio by adding first-in-class, early-in-lifecycle medicines such as TEPEZZA® (teprotumumab-trbw), KRYSTEXXA® (pegloticase) and UPLIZNA® (inebilizumab-cdon), which treat rare inflammatory diseases.
- Leveraging of Amgen’s world-class capabilities in biologics research and development, process development and manufacturing, as well as Amgen’s presence in more than 100 countries around the world.
- Generating robust cash flow to support capital allocation priorities, including ongoing investment in innovation while sustaining a commitment to an investment grade credit rating.
- Acceleration of revenue growth; expected to be accretive to non-GAAP earnings per share from 2024.
👉 AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC| Amgen
